Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) EBITDA Margin (2016 - 2020)

Historic EBITDA Margin for Forte Biosciences (FBRX) over the last 5 years, with Q1 2020 value amounting to 1361.11%.

  • Forte Biosciences' EBITDA Margin rose 1907277800.0% to 1361.11% in Q1 2020 from the same period last year, while for Mar 2020 it was 7781.89%, marking a year-over-year increase of 80759300.0%. This contributed to the annual value of 176341.67% for FY2019, which is 1760703000.0% down from last year.
  • Per Forte Biosciences' latest filing, its EBITDA Margin stood at 1361.11% for Q1 2020, which was up 1907277800.0% from 117955.56% recorded in Q4 2019.
  • Over the past 5 years, Forte Biosciences' EBITDA Margin peaked at 1800.0% during Q3 2016, and registered a low of 217811.11% during Q4 2018.
  • Moreover, its 5-year median value for EBITDA Margin was 99490.0% (2017), whereas its average is 90272.59%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2019, then skyrocketed by 1907277800bps in 2020.
  • Quarter analysis of 5 years shows Forte Biosciences' EBITDA Margin stood at 1616.67% in 2016, then plummeted by -6822bps to 108680.0% in 2017, then tumbled by -100bps to 217811.11% in 2018, then skyrocketed by 46bps to 117955.56% in 2019, then skyrocketed by 101bps to 1361.11% in 2020.
  • Its last three reported values are 1361.11% in Q1 2020, 117955.56% for Q4 2019, and 208311.11% during Q3 2019.